WCM Investment Management
PVLA

WCM Investment Management’s Palvella Therapeutics PVLA Stock Holding History

WCM Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22M Buy
40,140
+176
+0.4% +$21.4K 0.01% 174
2026
Q1 		$4.42M Buy
+39,964
New +$4.17M 0.01% 193

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

WCM Investment Management's PVLA Position: Q2 2026 in Review

WCM Investment Management increased its Palvella Therapeutics (PVLA) stake by 0.44% in Q2 2026, buying an estimated $21.4K and bringing the position to 40,140 shares worth $6.22M. The position accounts for 0.01% of the portfolio, ranked #174.

WCM Investment Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • WCM Investment Management held 40,140 shares of Palvella Therapeutics worth $6.22M as of Q2 2026.
  • WCM Investment Management bought 176 Palvella Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Palvella Therapeutics made up 0.01% of WCM Investment Management's portfolio in Q2 2026, its #174 holding.
  • WCM Investment Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on WCM Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.